Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcetacoplan in adults and adolescents with focal segmental glomerulosclerosis (sequential phase 2/3 study)
2025-524448-36-00Phase 3Authorised
- Sponsor
- Apellis Pharmaceuticals
- Start
- Jul 2026
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of pegcetacoplan in focal segmental glomerulosclerosis (FSGS) (3 arms), sponsored by Apellis Pharmaceuticals. Primary endpoints: Primary efficacy (phase 2) and Primary efficacy (phase 3). Planned start Jul 2026; status: authorised.
02
Drugs
pegcetacoplan
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on 2025-524448-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524448-36-00.